OnKure Therapeutics, Inc. Segments Disclosure
4. Segment
The Company is a publicly listed company focused on the development of clinical and pre-clinical product candidates with a reportable segment: clinical research. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.
The Company has yet to generate revenue and anticipates substantial expenses and operating losses as it advances its product candidates through clinical trials and regulatory processes.
The Company’s Chief Operating Decision Maker (“CODM”) is the senior executive committee that is comprised of the . The CODM assesses financial performance primarily using operating expenses as reported on the statement of operations, supplemented by internal budget and forecast models to guide resource allocation and performance evaluation. Segment assets are reported as total assets on the Company’s consolidated balance sheet, and segment loss is reflected as net loss in the Company’s consolidated statements of operations and comprehensive loss, effectively mirroring the Company’s
overall financial position due to its single-segment structure. The Company does not have intra-entity sales or transfers.
|
|
|
|
|
|
||
|
|
|
|||||
|
Clinical Research Segment |
|
|||||
|
2025 |
|
|
2024 |
|
||
|
|
|
|
|
|
||
|
(in thousands) |
|
|||||
Operating expenses: |
|
|
|
|
|
||
Direct program expense |
$ |
28,373 |
|
|
$ |
27,398 |
|
Indirect program expense |
|
1,923 |
|
|
|
2,157 |
|
Workforce salaries and benefits |
|
16,301 |
|
|
|
15,102 |
|
Share-based compensation expense |
|
11,633 |
|
|
|
4,530 |
|
General corporate expenses |
|
4,720 |
|
|
|
5,199 |
|
Interest and other expense |
|
8 |
|
|
|
300 |
|
Segment net loss |
|
62,958 |
|
|
|
54,686 |
|
Reconciliation of loss: |
|
|
|
|
|
||
Interest income |
|
(3,441 |
) |
|
|
(2,013 |
) |
Adjustments and reconciling items |
|
(3,441 |
) |
|
|
(2,013 |
) |
Net loss |
$ |
59,517 |
|
|
$ |
52,673 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 10, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.